Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Intarcia Therapeutics
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of T2D 3 months prior to the Screening Visit.
Body mass index (BMI) between ≥25 to ≤45 kg/m2 at the Screening Visit.
Glycosylated hemoglobin A1c (HbA1c) ≥7.5 and ≤10.5%. 5. 6. On a stable (3 months prior to the Screening Visit) treatment regimen of metformin monotherapy of ≥1500 mg/day).
You may not be if
History of type 1 diabetes.
Prior participation in a clinical study involving ITCA 650.
Treatment with any GLP-1 receptor agonist (eg, liraglutide, exenatide) within 6 months prior to Screening.
History or evidence, within the last 6 months prior to the Screening Visit, of myocardial infarction, coronary revascularization (coronary artery bypass grafting or percutaneous coronary intervention), unstable angina, or cerebrovascular accident or stroke.
History or evidence of acute or chronic pancreatitis.
History of medullary thyroid cancer or a family or personal history of multiple endocrine neoplasia type 2.
Treatment of medications that affect GI motility.
History of hypersensitivity to exenatide, empagliflozin, or glimepiride or to one of its excipients.
Women that are pregnant, lactating, or planning to become pregnant.
Chronic (\>10 consecutive days) treatment with systemic corticosteroids within 8 weeks prior to screening.
